Octave Specialty Group 配当と自社株買い
配当金 基準チェック /06
Octave Specialty Group配当金を支払った記録がありません。
主要情報
n/a
配当利回り
12.0%
バイバック利回り
| 総株主利回り | 12.0% |
| 将来の配当利回り | n/a |
| 配当成長 | n/a |
| 次回配当支払日 | n/a |
| 配当落ち日 | n/a |
| 一株当たり配当金 | n/a |
| 配当性向 | n/a |
最近の配当と自社株買いの更新
Recent updates
OSG: Steady Assumptions And Margins Will Support Future Upside Potential
Analysts have kept their $12.00 price target for Octave Specialty Group unchanged, citing only minor adjustments to projected revenue growth, profit margin, and future P/E assumptions as the key reasons for maintaining their view. What's in the News No recent news items, periodical coverage, or key developments for Octave Specialty Group were provided in the available sources.OSG: Faster Modeled Execution And Profitability Will Support Future Upside Potential
Analysts have kept their $12.00 price target for Octave Specialty Group unchanged, citing updated assumptions for faster revenue growth at 20.71%, a modestly higher profit margin at 11.06%, and a slightly lower forward P/E of 10.62, which together support the current valuation view. Valuation Changes Fair Value: Held steady at $12.00, with no change in the central valuation estimate.OSG: Completed Buybacks Will Tighten Float And Support Future Upside Potential
Analysts have kept their $12.00 price target for Octave Specialty Group unchanged, citing updated assumptions that include a slightly lower discount rate, adjusted revenue growth expectations of 15.54%, a profit margin estimate of 10.93%, and a projected future P/E of 12.26x. What's in the News From October 1, 2025 to December 31, 2025, Octave Specialty Group repurchased 3,142,554 shares for US$27.34 million, representing 6.73% of its shares.OSG: Completed Buybacks Will Tighten Float And Support Future Upside Potential
Analysts have kept their $12.00 price target for Octave Specialty Group unchanged, noting only slight adjustments to underlying assumptions such as discount rate, revenue growth, profit margin, and future P/E, which they view as offsetting each other overall. What's in the News Between October 1, 2025 and December 31, 2025, Octave Specialty Group repurchased 3,142,554 shares, representing 6.73% of its shares, for $27.34 million under its existing buyback program (Key Developments).OSG: Share Repurchases Will Tighten Float And Support Future Upside Potential
Analysts now maintain their price target for Octave Specialty Group at $12.00, citing similar fair value and margin assumptions, with only modest adjustments to revenue growth, the discount rate, and future P/E inputs. What's in the News Completed share repurchase of 4,371,886 shares, representing 9.33% of outstanding shares, for a total of $42.45 million under the buyback announced on November 12, 2024 (Key Developments).OSG: Share Repurchases Will Support Future Upside Potential
Analysts now hold their price target for Octave Specialty Group at $12.00, reflecting slightly updated assumptions for revenue growth, profit margins, discount rate, and future P/E that fine tune rather than overhaul their prior view. What's in the News Completed share repurchase program with a total of 4,371,886 shares bought back for $42.45 million, representing 9.33% of shares under the buyback announced on November 12, 2024 (Key Developments).OSG: Share Repurchases And Auditor Shift Will Support Future Upside Potential
Analysts have reduced their price target on Octave Specialty Group from $15.00 to $12.00, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. What's in the News Completed share repurchase of 4,371,886 shares in total, representing 9.33% of shares, for $41.69 million under the buyback announced on November 12, 2024.OSG: Auditor Transition And Execution Will Support Future Upside Potential
Analysts have adjusted their price target on Octave Specialty Group to $15.00. This change reflects updated assumptions around slightly higher projected revenue growth, a modestly stronger profit margin, and a lower future P/E multiple.OSG: ArmadaCare Execution And Organic Expansion Will Support Future Upside Potential
Analysts have raised their price target on Octave Specialty Group to $15 from $10, citing updated models that incorporate recent earnings, higher assumed organic growth, and the impact of the ArmadaCare deal. Analyst Commentary While the new US$15 price target signals higher modeled value for Octave Specialty Group, not all of the commentary behind the scenes is purely optimistic.OSG: Higher Growth Assumptions And ArmadaCare Integration Will Drive Future Upside
Narrative Update Analysts have lifted their price target on Octave Specialty Group to US$15 from US$10, citing refreshed models that factor in higher assumed organic growth, the ArmadaCare acquisition and recent quarterly performance. Analyst Commentary While the higher US$15 target reflects more constructive modeling around organic growth and the ArmadaCare acquisition, not all commentary skews optimistic.OSG: Earnings Beat And ArmadaCare Integration Will Support Long-Term Share Gains
Analysts have raised their price target on Octave Specialty Group by $5 to $15, citing updated models that incorporate Q3 earnings, revised assumptions for organic growth, and the expected impact of the ArmadaCare transaction. Analyst Commentary Bullish Takeaways Bullish analysts point to the updated Q3 earnings model as support for the new US$15 price target, arguing that current valuation better reflects Octave Specialty Group's recent financial results.OSG: Earnings Beat And Deals Will Drive Long-Term Shareholder Upside
Analysts raised their price target for Octave Specialty Group by $5, increasing it to $15 from $10. They cited updated models that reflect stronger assumed organic growth following an earnings beat and recent strategic transactions, which they believe support a path to sustained elevated expansion.OSG: Q3 Earnings Beat Will Support Long-Term Shareholder Value Expansion
Analysts raised their price target on Octave Specialty Group to $15 from $10, citing updated models that reflect stronger than expected Q3 performance, higher assumed organic growth, and incremental upside from recent strategic deals. Analyst Commentary Analysts note that the revised price target for Octave Specialty Group is grounded in tangible improvements to the company’s growth profile, as well as rising confidence in management’s ability to execute on recent strategic initiatives.OSG: Sustained Organic Expansion Will Drive Long-Term Shareholder Value
Analysts have raised their price target for Octave Specialty Group, increasing it by $5 to reflect stronger than expected organic growth and recent strategic acquisitions. Analyst Commentary Following the recent price target increase, analysts have provided additional context regarding their views on Octave Specialty Group's prospects.AMBC: Revenue Momentum and Armada Acquisition Will Drive Further Share Upside
Analysts have raised their price target for Octave Specialty Group from $14.67 to $16.33. They cite stronger projected revenue growth and improved profitability metrics in their updated outlook.Ambac: Surprise Acquisition Changes Outlook (Rating Downgrade)
Summary Ambac is downgraded to Hold following the surprise $250M ArmadaCare acquisition after selling its legacy guarantee business. The new deal adds product diversification and potential growth, but reintroduces debt and increases risk to the balance sheet. Management maintains 2028 adjusted EBITDA guidance at $80M–$90M, despite the significant size of the ArmadaCare acquisition. I recommend waiting for a lower entry price below $7 or more clarity in Q3 results before considering AMBC a Buy again. Read the full article on Seeking AlphaUS Infrastructure Spending And Automation Will Unlock Insurance Potential
Diversification into specialty insurance and tech-driven operations is improving revenue stability, earnings quality, and operational efficiency.Ambac: Despite EPS Miss, It's A Growth Company
Summary Ambac Financial Group saw a stock decline after an earnings miss for Q4. Such a sell-off overlooks the fundamental improvements: profitable underwriting and the build-out of a higher-ROE distribution platform. The sale of the legacy business remains to be approved by Wisconsin, creating a thorn in AMBC's side for the moment. Management, however, was eager about the growth ahead; the current price is a small P/E for earnings in just a few years. Read the full article on Seeking AlphaAmbac Financial: Don't Get Lost In The Weeds; It's Working
Summary Ambac Financial Group has shifted from guarantee insurance to specialty property-casualty insurance and distribution. Despite a drop in tangible book value per share, the sale of the legacy business and recent acquisitions are expected to improve financials and boost earnings. Ambac Financial faces risks from recent hurricanes and potential delays in the legacy business sale approval, but overall outlook remains positive. I maintain a Buy rating on AMBC stock, believing Ambac's turnaround strategy will lead to better capitalization and improved earnings, offering a favorable risk-reward asymmetry. Read the full article on Seeking AlphaAmbac Financial: Unbundling The Recent Sale And The New Acquisition
Summary Ambac sold its Financial Guarantee business to Oaktree at a disappointing valuation, causing a 20% drop in stock price. The company reinvested proceeds into acquiring a majority stake in Beat Capital Partners for $280 million at a generous valuation, raising concerns among investors. Despite the negative stock reaction, a new valuation framework suggests a fair value per share of around $15, indicating a 20% upside potential. Read the full article on Seeking AlphaAmbac: Finally Shaking Off The Great Financial Crisis
Summary Ambac Financial Group has undergone a turnaround after the 2008 Financial Crisis, improving its financial position and evolving its business model. The company's balance sheet appears healthy and able to meet upcoming obligations, with a new focus on specialty property-casualty insurance. AMBC is positioning itself to underwrite its products through a technology-driven MGA model, aiming to take advantage of the growing US market with attractive loss ratios. Yet, investors should remember that the discount exists for a reason, given how a recession could particularly affect a company like this. Read the full article on Seeking AlphaAmbac: Releasable Liquidity And SOTP Analysis Reveals Upside Potential
Summary Ambac is a complex company with a financial guarantees business and a new specialty P&C insurance business. We run a comparison with MBIA to compute releasable liquidity from the FG business that may be paid out as a special dividend. Ambac may benefit from a liquidity release or a sale, but the bulk of its value lies in its new businesses. Read the full article on Seeking AlphaAmbac Financial Group Inc: Debt Trap Disguised As Value Opportunity
Summary Ambac Financial Group Inc is trading at low multiples but has a significant amount of debt that is impacting its expansion capacities. AMBC operates through two divisions, Everspan and Cirrata, and presents itself as an opportunity in the growing specialty coverage market. The company's high debt levels and inconsistent bottom line make it a risky investment, and the share price is expected to decline further. Read the full article on Seeking AlphaAmbac Remains Discounted By An Apprehensive Market
Summary Ambac has seen significant price appreciation since the announced settlement with Bank of America and Nomura Holdings. Alongside aggressive growth from Cirrata, shareholders can expect effective organic and inorganic growth from Ambac. Despite these factors, Ambac still trades at a 23% undervaluation, leading me to rate the company a 'buy'. Read the full article on Seeking AlphaAmbac settles with Nomura, closing financial crisis-era RMBS lawsuits
Ambac Financial Group (NYSE:AMBC) said Tuesday its Assurance Corporation subsidiary (AAC) entered into a settlement agreement with Nomura (NYSE:NMR) that will give AAC $140M. The settlement brings to an end all of Ambac's (AMBC) legacy residential mortgage-backed securities representation and warranty litigation that arose from the 2008 financial crisis. In October, Bank of America (BAC) agreed to pay Ambac $1.8B to settle litigation related to mortgage company Countrywide's collapse during the crisis. The settlement exceeds the amount of recovery recorded on Ambac's (AMBC) Q3 2022 GAAP financial statements attributed to the Nomura (NMR) litigation. As a result, the company will record a gain of ~$43M in its Q4 financial statement. Last month, Street Insider reported that Assured Guaranty (AGO) and Ambac Financial (AMBC) had made bids for rival MBIA (MBI).決済の安定と成長
配当データの取得
安定した配当: OSGの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。
増加する配当: OSGの配当金が増加しているかどうかを判断するにはデータが不十分です。
配当利回り対市場
| Octave Specialty Group 配当利回り対市場 |
|---|
| セグメント | 配当利回り |
|---|---|
| 会社 (OSG) | n/a |
| 市場下位25% (US) | 1.4% |
| 市場トップ25% (US) | 4.2% |
| 業界平均 (Insurance) | 2.6% |
| アナリスト予想 (OSG) (最長3年) | n/a |
注目すべき配当: OSGは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。
高配当: OSGは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。
株主への利益配当
収益カバレッジ: OSGの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。
株主配当金
キャッシュフローカバレッジ: OSGが配当金を報告していないため、配当金の持続可能性を計算できません。
高配当企業の発掘
企業分析と財務データの現状
| データ | 最終更新日(UTC時間) |
|---|---|
| 企業分析 | 2026/06/16 11:19 |
| 終値 | 2026/06/16 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Octave Specialty Group, Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7
| アナリスト | 機関 |
|---|---|
| Giuliano Anderes Bologna | BTIG |
| Mary Kane | Citigroup Inc |
| Giuliano Anderes Bologna | Compass Point Research & Trading, LLC |